<- Go Home
Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Market Cap
$95.6M
Volume
138.4K
Cash and Equivalents
$52.2M
EBITDA
-$12.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$13.0K
Profit Margin
0.65%
52 Week High
$3.09
52 Week Low
$1.82
Dividend
N/A
Price / Book Value
0.48
Price / Earnings
2.34
Price / Tangible Book Value
0.48
Enterprise Value
-$39.1M
Enterprise Value / EBITDA
3.11
Operating Income
-$13.0M
Return on Equity
24.48%
Return on Assets
-4.22
Cash and Short Term Investments
$134.7M
Debt
$860.0K
Equity
$202.3M
Revenue
$2.0M
Unlevered FCF
-$4.1M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium